It looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.
Switch to US ($)
Whether you are developing new immunotherapies for dogs or conducting veterinary research, our new dog antibody library was designed to give you the best reagents in less than 7 weeks. Endowed with huge diversity (1010), LibAb-SFDogTM bears the native repertoire of dozens of dogs from many different breeds. It is the first high-diversity naïve canine antibody library on the market.
Outstanding clonal diversity of 1 x 1010 (scFv/Fab) obtained from samples of 46 individual dogs from 6 different breeds
Get your native canine antibody in less than 7 weeks, ready for therapy or veterinary medicine research
Antibody caninization processes are time-consuming, expensive, and risky. Save time and costs by opting for a therapy-ready and application-ready dog antibody discovery process
Receive at least 3 unique binders against your target antigen
Get full ownership over all generated native canine antibodies
Forgo the need for immunization thanks to the high diversity of our premium LiAb-SFDogTM library and the screening power of our phage display platform
Our new dog library (LiAb-SFDogTM) is the first naïve and high-diversity library on the market.
| Library | Species | Format | Size (clones) |
|---|---|---|---|
| LiAb-SFDogTM | 46 healthy dogs from 6 different breeds: Beagle, German Shepherd, Labrador, English Coonhound, Great Dane, Chinese Rural Dog | scFv | 1.05 x 1010 |
| LiAb-SFDogTM | 46 healthy dogs from 6 different breeds: Beagle, German Shepherd, Labrador, English Coonhound, Great Dane, Chinese Rural Dog | Fab | 1.01 x 1010 |
Antigen procurement or design and production
Library screening and biopanning
ELISA screening of single phage binders
Phage DNA extraction & antibody sequencing
Additional screening & analysis (optional)
In the past decade, the use of immunotherapies in veterinary medicine has been gaining ground over conventional treatments. But one of the major challenges still hindering their widespread use is the limited availability of canine-specific reagents, vital to better understand dogs’ immune systems. Additionally, there are still significant gaps in knowledge concerning the genotype and phenotype of tumors in dogs and corresponding disease biomarkers. Although these limitations hamper the efforts of immunotherapy development for dogs, they also create an unprecedented opportunity for progress.
The lack of native antibodies was the main driving force behind the generation of our new premium dog antibody library – LiAb-SFDogTM. Being the first of its kind on the market, it offers an avenue for quickly generating antibodies for veterinary research and therapy. But what is known about the use of monoclonal antibodies to treat animals?
The proof that canine cancer was responsive to immunotherapy was provided in the 1960s with the first successful bone marrow transplant between littermates. Since then, the use of immunotherapy in dogs was shown to successfully tackle conditions such as sarcoma, lymphoma, mammary cancer, arthritis, dermatitis, and parvovirus infections, among others.
Antibodies are a hallmark of human medicine. In comparison, the development of new dog immunotherapeutics has lagged considerably. Currently, only a few therapies are commercially available in the USA and Canada:
In comparison to their human equivalents, these antibodies have shown limited effectiveness. One reason for this limitation may stem from the fact that these therapeutics have been developed by a process of caninization.
As the name indicates, this process is similar to antibody humanization. However, our limited knowledge regarding dog immunology has made caninization significantly more risky, expensive, and time-consuming than the humanization process. Moreover, disease targets may differ significantly between dogs and humans, making the process of target selection and antigen design suboptimal when it comes to the treatment of canine diseases.
The canine immune system is more similar to humans than the mouse’s immune system. Like humans, dogs of a certain age have a very immunologically experienced system caused by repeated exposure to antigens and multiple immunizations.
Dogs also share the same environment as their human companions. For this reason, they are exposed to many of the same allergens, food antigens, and environmental chemicals. Therefore, dogs’ immune response is more analogous to humans.
unlike implanted mouse tumors, dogs develop cancer naturally, closer to human disease progression. Therefore, dogs’ immune response is more analogous to humans.
Due to their large size (often comparable to that of a human child), drugs administrated to dogs based on their weight or body surface area are much more likely to result in an accurate drug activity and toxicity profile. In contrast, mice are frequently treated with much higher doses, often toxic to humans, making them ill-suited to estimate dose-response relationships.
Also due to their large size, access to blood and tissue samples is more straightforward in dogs in comparison to rodents. This facilitated access allows closer monitoring of the progression of the immune response to different treatments and dosage regimens.
